Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “intend”, “estimate”, “predict”, “potential”, “continue” or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at www.sedar.com. Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.
Our goal is to be a leading company in developing novel therapies for serious and unmet medical needs

Founded in 2012, repurposing clinically validated drugs with no drug approvals in U.S./EU/Japan

Advanced Bucillamine in FDA approved Phase 2 clinical studies for gout and cystinuria

Identify drugs with proven safety, lower development cost and faster-to-market

Focusing on neuropathic pain, inflammatory skin disorders, and liver diseases

Developing novel topical drug delivery system for cannabinoids

Advancing research, development and validation of a number of cannabinoids for liver diseases

Expanding product pipeline via R&D, licensing and strategic partnering
### PRODUCT PIPELINE

Expanding pipeline with therapies known to be safe, potentially effective, lower risk development, faster-to-market

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Project Market Size</th>
<th>Research</th>
<th>Preclinical / IND-enabling</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>REV-100 CBD Gel</td>
<td>Neuropathic Pain</td>
<td>$8 Billion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REV-101 CBD Gel</td>
<td>Inflammatory Skin Disorders</td>
<td>$5 Billion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REV-200 Cannabidiol</td>
<td>Liver Inflammation</td>
<td>$500 Million</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REV-201 Undisclosed</td>
<td>NALFD and Liver Fibrosis</td>
<td>$20 Billion</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REV-004 (Bucillamine)</td>
<td>Cystinuria (Kidney Stones)</td>
<td>$500 Million</td>
<td></td>
<td>Granted FDA Orphan Drug Designation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>REV-002 (Bucillamine)</td>
<td>Gout (Acute flares)</td>
<td>$250 Million</td>
<td></td>
<td>Phase 2b ready, Seeking Pharma Partner</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Developing CBD topical gel in partnership with University of Wisconsin-Madison
- Initiated Phase 2 clinical study
- Phase 2b ready, Seeking Pharma Partner
CANNABINOID OPPORTUNITY

- Cannabinoids shown to bind to receptor sites CB-1 (brain) and CB-2 (body)
- Potential to treat a number of disorders including inflammation, pain, and cancer
- Over 80 cannabinoids identified; may offer a lower risk development opportunity (established safety and potential efficacy)
- Cannabinoid products approved in US or EU: Sativex™ (GW Pharma), Marinol™ (AbbVie), Cesamet™ (Meda)
- 21st Century Cures Act to accelerate cannabinoid drug development offering a significant untapped opportunity

Valuations of Cannabinoid-based companies
- GW Pharma – approx. USD $2.5 billion market cap
- Insys – approx. USD $650 billion market cap
- Zynerba – approx. USD $100 million market cap
CANNABIDIOL (CBD) TOPICAL GEL

Developing proprietary CBD Topical Gel
- Research and Option to License Agreement with WARF
- Sponsored Research Agreement with University of Wisconsin

Potential advantages of CBD Topical Gel
- Avoids GI tract difficulties and first-pass liver metabolism
- Enables a steady blood-level profile (improved efficacy)
- Reduced side effects and improves patient compliance

Proposed proprietary CBD Topical Gel
- CBD in combination with chitosan (blood-clotting and antimicrobial properties) and tannins (antibacterial, antifungal, antioxidant and wound healing properties)

Potential of the drug delivery technology
- Improved stability and higher drug loading capacity
- Better drug release properties and improved cell uptake
- Greater porosity, improved tensile strength, increased thermal stability and non-cytotoxic

CBD Topical Gel potential indications
- Neuropathic pain, inflammatory skin disorders, skin complications (acne), wound healing

Research and Option to License Agreement for U.S. Patent No. 8642088
CBD TOPICAL GEL FOR NEUROPATHIC PAIN

- Neuropathic pain from damage to the nerves in the peripheral nervous system

- Neuropathic Indications
  - Herpes zoster, shingles, diabetes, chemotherapy, HIV
  - Lower back pain, cancer-related neuropathic pain
  - Complex regional pain syndrome, postop neuropathic pain

- Current treatment options have many drawbacks, including poor tolerability with side effects in most patients

- Market Opportunity
  - Approximately 15.2 million patients in the U.S. (CDC)
  - U.S. market size of ~ $3.3 billion in 2017
  - Global market size of ~ $8.3 billion by 2024
CBD TOPICAL GEL FOR INFLAMMATORY SKIN

- Inflammatory skin disorders are the results of immune system reactions
- Indications include dermatitis (eczema), rosacea, and psoriasis
- **Dermatitis Market Opportunity**
  - ~31 million patients in the U.S. and ~$4 billion market size
  - Steroids are main treatment option but only address symptoms
- **Psoriasis Market Opportunity**
  - ~7.5 million patients in the U.S. and ~$20 billion market size
  - Biologics are main treatment but have serious side effects and are very expensive
- CBD topical gel potential market size opportunities to treat acne ($4.5B market) and ulcers/wounds ($8.5B market)
LIVER DISEASE OPPORTUNITY

- Liver disease defined by improper functioning of liver, causing disorders like hepatitis, fatty liver, and cirrhosis
- Growth drivers of liver disease include rapidly changing lifestyle patterns (alcohol, unhealthy diets)
- Liver disease market to reach $19.5 Billion by 2022
- Over 100 different types of liver diseases affecting at least 30 million people in the U.S. alone
- Pharma deals in liver disease
  - Allergan acquisition of Tobira Therapeutics for $1.7 Billion
  - Novartis/Conatus license – $50M upfront, $650M milestones
  - Gilead acquisition of Nimbus Therapeutics for up to $1.2 Billion
CANNABINOIDs FOR NAFLD / LIVER FIBROSIS

- Targeting Non-Alcoholic Fatty Liver Disease (build up of fat in the liver) and Liver fibrosis (scar formation)

**Market Opportunity**
- Global epidemic with 1 out of 4 people affected
- Potential global market of $35-$40 billion by 2025 (Deutsche Bank)
- U.S. market of $25 billion by 2025 (fastest growing segment in hepatology)

- Revive initiated research, development and validation of a number of cannabinoids for liver diseases
- Building liver franchise of cannabinoids and next generation compounds
- Potential expansion into other liver diseases via R&D, licensing, partnering

---

[Diagram: Stages of liver damage]
BUCILLAMINE FOR CYSTINURIA

Unmet Need to Treat Cystinuria

Rare disease (20k patients in US)
- Stones from cysteine form in kidney and bladder

Significant limitations with existing drugs
- Limited efficacy, poor side effects, high doses & costs

Bucillamine potential to prevent stones
- Repurposed, 30 year history (arthritis drug in Japan)
- Clinical proof-of-concept (superior than competitor*)
- Potential to improve efficacy (dual cystine binding)
- Opportunity to lower dosing & reduce side effects

$500 Million Market Opportunity
(5,000 patients x $100,000 per patient per year)

Received U.S. FDA orphan drug status for cystinuria
7-year market exclusivity

Initiated US Phase 2 clinical study
FDA IND accepted in 2016

Phase 3 in 2018 Approval by 2020
Seek pharma partner

BUCILLAMINE FOR GOUT

Bucillamine for gout
U.S. Patent expires 11/2033

Completed Phase 2a
Achieved positive results

Ready for Phase 2b study
Seeking pharma partner

Unmet Need to Treat Gout Flares

8 million diagnosed with gout in U.S.
- High prevalence to other diseases (65% have >1)
- Hypertension (~70-80%), Diabetes (~25-40%), Chronic Kidney (~40%), Coronary Artery (~40%)

Significant drug therapy limitations
- 90% contraindicated to NSAIDs and steroids
- 50%-66% contraindicated to colchicine
- 38% responded to colchicine in clinical study

Peer analysis suggest Revive’s current market value between $100 and $150 million

<table>
<thead>
<tr>
<th>Feature</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revive undervalued relative to Cannabinoid focused and Phase 2 stage companies</td>
<td></td>
</tr>
<tr>
<td>Novel and early stage Cannabinoid programs with scientific rationale and safety</td>
<td></td>
</tr>
<tr>
<td>Bucillamine has proof-of-concept efficacy and proven safety through decades of use</td>
<td></td>
</tr>
<tr>
<td>Near-term and early stage development partnering potential</td>
<td></td>
</tr>
<tr>
<td>Strong Scientific Advisory Board and focus on intellectual property</td>
<td></td>
</tr>
</tbody>
</table>
REV-100: Commence topical gel formulation development – Q3
REV-100: Optimize topical gel formulation – Q3
REV-100: Complete permeation studies – Q3
REV-200: Sign license agreement University of South Carolina – Q3
REV-100: Results for anti-inflammatory and wound infections – Q4
REV-100: Animal studies for pain and skin disorders – Q4
REV-200: Animal studies and MOA studies – Q4
REV-004: Complete Phase 2 study – 4Q
REV-201: Animal studies in fibrosis / NAFLD models – Q3/4

Target Patent Filings - 3Q-4Q
REV-200: Engage regulatory (FDA) to commence studies – Q1-2018
REV-201: Engage regulatory (FDA) for development path – Q1-2018
REV-100: Engage regulatory (FDA) to commence studies - Q1-2018
Commence partnering initiatives for REV-004/5, drug delivery technology, pipeline – Q1-2018
## EXECUTIVE TEAM AND ADVISORS

### Management Team and Advisors

- **Craig Leon**, Chairman and CEO - Titan Medical (OTCQX: TITXF)
- **Fabio Chianelli**, President and Director - Titan Medical, Generex
- **Carmelo Marrelli**, Chief Financial Officer - CFO to TSX listed firms
- **Dr. Bev Incledon**, VP, Research and Development - Highland Therapeutics, Exec VP, R&D
- **Dr. Lee Simon**, Regulatory Affairs Advisor - FDA's Division Director of Analgesic, Anti-inflammatory Drug Products
- **Dr. Scott Friedman, MD**, Scientific Advisor - Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at Icahn School of Medicine at Mount Sinai
- **Dr. Arun Sanyal, MD**, Scientific Advisor - Professor of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine
- **Dr. Ram Subramanian, MD**, Scientific Advisor - Medical Director Liver Transplantation at Emory Hospital
- **Dr. Pritesh Kumar, Phd**, Scientific Advisor - Cannabinoid pharmacology at University of Louisville

### Board of Directors

- **Craig Leon**, Chairman and CEO - Titan Medical (OTCQX: TITXF)
- **Fabio Chianelli**, President and Director - Titan Medical, Generex
- **William Jackson**, Director - Atwill Medical Solutions
- **Carlo Sansalone**, Director - Sanscon
<table>
<thead>
<tr>
<th><strong>Ticker Symbols</strong></th>
<th>RVV (TSX Venture)</th>
<th>RVVTF (OTCQB)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Share Price</strong></td>
<td>CAD $0.185 (August 9, 2017)</td>
<td></td>
</tr>
<tr>
<td><strong>52 week High/Low</strong></td>
<td>CAD $0.44 / $0.095</td>
<td></td>
</tr>
<tr>
<td><strong>Avg. Volume (3-months)</strong></td>
<td>~ 195,000 shares a day</td>
<td></td>
</tr>
<tr>
<td><strong>Capital Structure</strong></td>
<td>53,893,567 common shares (61,400,882 fully-diluted)</td>
<td></td>
</tr>
<tr>
<td><strong>Market Cap</strong></td>
<td>CAD ~ $10,000,000</td>
<td></td>
</tr>
<tr>
<td><strong>Cash and Cash Equivalents</strong></td>
<td>CAD $2,222,994 (unaudited March 31, 2017)</td>
<td></td>
</tr>
<tr>
<td><strong>Cash Burn/Month</strong></td>
<td>CAD ~ $175,000</td>
<td></td>
</tr>
<tr>
<td><strong>Analyst Coverage</strong></td>
<td>Beacon Securities – Doug Cooper – BUY $3.00</td>
<td></td>
</tr>
</tbody>
</table>

**Warrants:**
- 5,665,315 Warrants @$0.18 (expire June 18, 2018)
- 197,750 Finder's Warrants @$0.10 (one common share and one-half warrant @$0.18)

**Stock Options:**
- 2,518,151 stock options (925,000 @ $0.60; 590,000 @ $0.66; 38,151 @ $0.30; 965,000 @ $0.28) as of April 20, 2017
Advancing novel therapies for serious and unmet medical needs

Product pipeline of therapies known to be safe, potentially effective, lower risk development, faster-to-market potential

Targeting liver diseases, neuropathic pain, and inflammatory skin disorders

Focus on validating topical drug delivery system for cannabinoids

Experience with FDA clinical studies

Partnering with early and later stage development programs